Embracing Age: A New Scientific Roadmap to Tackle Parkinson’s

For decades, scientific research into Parkinson’s has focused primarily on the biological mechanisms of the condition itself—the proteins that misfold and the neurons that struggle to survive. However, an international team of researchers, including experts from the Buck Institute, is now arguing that we have been missing the most significant piece of the puzzle: the biological process of ageing. In a newly released roadmap, scientists are calling for a fundamental shift in how we study the condition, placing the intersection of ageing and Parkinson's at the very heart of future discovery. Ageing as the Primary Risk Factor While genetics and environmental exposures play a role, ageing remains the single largest risk factor for developing Parkinson’s. Despite this, a vast majority of laboratory research has historically used "young" biological models to study a condition that predominantly affects people in later life. This disconnect may explain why many treatments that show promise in the lab do not always translate into successful therapies for people. The new roadmap, titled Unraveling the Intersection of Aging and Parkinson’s Disease, highlights that many age-related changes in the brain actually mirror the early stages of the condition. Biological hallmarks of ageing—such as mitochondrial dysfunction, increased inflammation, and cellular senescence—are the same processes that contribute to the progression of Parkinson's. By viewing the condition through the lens of ageing, researchers believe they can identify "gerotherapeutic" targets—treatments that address the underlying biology of ageing to slow or prevent the condition entirely. Moving Beyond Family History A common misconception is that Parkinson's is strictly a genetic condition. In reality, only about 10% of cases are linked to family history. The remaining 90% are "sporadic," arising from a complex, lifelong interaction between a person’s genetic vulnerability and their environment. The research team points out that the influence of ageing on the condition is subtle and gradual, often acting as a catalyst that allows other risk factors to take hold. To address this complexity, the roadmap provides clear guidelines for using better research models. This include standardising how scientists use older animal models and human cell cultures to ensure that the "background" of an ageing brain is always considered. This collaborative effort, funded by the Michael J. Fox Foundation, aims to foster international cooperation and ensure that resources are used as effectively as possible to find a cure. A Holistic Future for Research The goal of this new roadmap is to make it easier for scientists across the globe to incorporate ageing into their daily work. Rather than treating Parkinson’s as an isolated event, the scientific community is moving towards a more holistic approach. If the biology of ageing is malleable—as many modern scientists now believe—then targeting the ageing process itself could offer a way to protect the brain from neurodegeneration. For people living with the condition, this shift in focus offers a new wave of hope. It suggests that future treatments won't just patch up the symptoms but will instead address the very environment in which the condition thrives. By understanding how our bodies age, we are getting closer to a world where we can preserve the health and vitality of the brain for decades longer.